NewsBenzingaBMO Capital mantiene il giudizio Outperform su Alnylam Pharmaceuticals e alza il prezzo obiettivo a 293 dollari BMO Capital mantiene il giudizio Outperform su Alnylam Pharmaceuticals e alza il prezzo obiettivo a 293 dollari Benzinga 2026.11.20 16:22 (GMT+0) Open on Benzinga Other news AI Stocks' Wild Ride Gets Bumpier As Nvidia Chaos, Blue Tsunami Spook Investors Stock Market Dives To New Lows Despite Nvidia Earnings, Anthropic IPO: Weekly Review Could Jensen Huang Land At Nvidia Rival Intel? BMO Capital Maintains Market Perform on BILL Holdings, Lowers Price Target to $63.25 Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer BMO Capital Maintains Market Perform on Bath & Body Works, Lowers Price Target to $20